Reviva Pharmaceuticals Holdings, Inc. RVPH
We take great care to ensure that the data presented and summarized in this overview for REVIVA PHARMACEUTICALS HOLDINGS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RVPH
View all-
Vanguard Group Inc Valley Forge, PA1.8MShares$811,8410.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.53MShares$690,4420.0% of portfolio
-
Diadema Partners LP Morristown, NJ651KShares$292,8250.16% of portfolio
-
Tang Capital Management LLC San Diego, CA510KShares$229,6480.03% of portfolio
-
Geode Capital Management, LLC Boston, MA419KShares$188,6120.0% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY258KShares$116,1880.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA231KShares$104,1520.0% of portfolio
-
Simplex Trading, LLC228KShares$102,6290.0% of portfolio
-
Ubs Group Ag224KShares$100,5930.0% of portfolio
-
Marshall Wace, LLP London, X0216KShares$97,4240.0% of portfolio
Latest Institutional Activity in RVPH
Top Purchases
Top Sells
About RVPH
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention?deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.
Insider Transactions at RVPH
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 18
2022
|
Purav Patel Director |
BUY
Open market or private purchase
|
Direct |
3,000
+6.45%
|
$12,000
$4.69 P/Share
|
|
Sep 30
2022
|
Prabhu Narayan Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
50,000
+33.33%
|
$50,000
$1.66 P/Share
|
|
Jun 30
2022
|
Prabhu Narayan Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
50,000
+50.0%
|
$50,000
$1.21 P/Share
|
|
Jun 01
2021
|
Vedanta Partners, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,330,000
+50.0%
|
$3,990,000
$3.75 P/Share
|
|
Dec 14
2020
|
Tenzing LLC Director |
BUY
Grant, award, or other acquisition
|
Direct |
197,500
+8.52%
|
-
|
|
Dec 08
2020
|
Glazer Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
367,000
-100.0%
|
$3,670,000
$10.88 P/Share
|
|
Dec 08
2020
|
Hudson Bay Capital Management LP > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
710,000
-100.0%
|
$7,100,000
$10.88 P/Share
|
|
Dec 07
2020
|
Hudson Bay Capital Management LP > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
50,000
-6.58%
|
$550,000
$11.51 P/Share
|
|
Dec 03
2020
|
Glazer Capital, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
606,360
-100.0%
|
$6,063,600
$10.88 P/Share
|
|
Dec 02
2020
|
Glazer Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
261
-0.04%
|
$2,871
$11.0 P/Share
|
|
Dec 01
2020
|
Glazer Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
5,362
-0.88%
|
$58,982
$11.0 P/Share
|
|
Nov 27
2020
|
Glazer Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
5,969
-0.97%
|
$59,690
$10.9 P/Share
|
|
Nov 24
2020
|
Glazer Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
7,103
-1.14%
|
$71,030
$10.9 P/Share
|
|
Nov 23
2020
|
Glazer Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
23,611
-3.64%
|
$236,110
$10.9 P/Share
|
|
Nov 18
2020
|
Glazer Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
896
-0.14%
|
$8,960
$10.9 P/Share
|
|
Nov 17
2020
|
Glazer Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
127
-0.02%
|
$1,270
$10.9 P/Share
|
|
Nov 16
2020
|
Glazer Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
305
-0.05%
|
$3,050
$10.9 P/Share
|
|
Nov 11
2020
|
Glazer Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
5
-0.0%
|
$50
$10.9 P/Share
|
|
Nov 06
2020
|
Glazer Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1
-0.0%
|
$10
$10.9 P/Share
|
|
Nov 03
2020
|
Glazer Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
57,616
-8.14%
|
$576,160
$10.85 P/Share
|